文献速递血栓与止血

COVID-19血栓灾难与补体系统相关吗

Is the COVID-19 thrombotic catastrophe complement-connected?
PubMed 文献 · J Thromb Haemost · 2020-09-18

该综述提出,SARS-CoV-2感染导致的多系统疾病(COVID-19)存在高血栓风险,伴促炎细胞因子、D-二聚体和纤维蛋白原显著升高但无弥散性血管内凝血;尸检证实静脉血栓栓塞高发及弥漫性微血管血栓、内皮肿胀和肺泡间隔补体活化片段沉积,表现类似非典型溶血性尿毒症综合征(aHUS)。作者汇总证据提示补体参与致病性冠状病毒相关血栓形成的病理生理,并建议探索新型治疗靶点及现有抗补体药物治疗COVID-19的临床试验依据。

要点

  • COVID-19血栓风险高,伴促炎细胞因子、D-二聚体和纤维蛋白原显著升高,但无弥散性血管内凝血。
  • 尸检证实静脉血栓栓塞高发,并见弥漫性微血管血栓、内皮肿胀和肺泡间隔补体活化片段沉积。
  • 作者认为补体过度活化可能触发和/或加剧SARS-CoV-2感染相关血栓并发症,建议开展抗补体治疗临床试验。

核心结论

  • 作者提出不断增多的证据表明补体参与致病性冠状病毒(包括SARS-CoV-2)相关血栓素质的病理生理。
  • 作者建议基于当前对补体、凝血和病毒的认识,确定新型治疗靶点并为现有抗补体药物治疗COVID-19的临床试验提供依据。

研究设计与样本

  • 综述,围绕补体在致病性冠状病毒相关血栓形成中的作用汇总现有证据。

主要发现

  • COVID-19可累及多器官,血栓风险高,伴促炎细胞因子、D-二聚体和纤维蛋白原显著升高,但无弥散性血管内凝血。
  • 尸检研究证实静脉血栓栓塞发生率高,并见弥漫性微血管血栓伴内皮肿胀,符合血栓性微血管病,以及肺泡间隔补体活化片段沉积。
  • COVID-19的临床病理表现与补体系统失调所致的非典型溶血性尿毒症综合征(aHUS)等血栓性疾病相似。

临床怎么用

  • 作者认为现有抗补体治疗在aHUS中保护血栓高度有效,可能在COVID-19中有效。
  • 作者建议开展临床试验以评估现有抗补体药物治疗COVID-19的依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In December 2019, the world was introduced to a new betacoronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for its propensity to cause rapidly progressive lung damage, resulting in high death rates. As fast as the virus spread, it became evident that the novel coronavirus causes a multisystem disease (COVID-19) that may involve multiple organs and has a high risk of thrombosis associated with striking elevations in pro-inflammatory cytokines, D-dimer, and fibrinogen, but without disseminated intravascular coagulation. Postmortem studies have confirmed the high incidence of venous thromboembolism, but also notably revealed diffuse microvascular thrombi with endothelial swelling, consistent with a thrombotic microangiopathy, and inter-alveolar endothelial deposits of complement activation fragments. The clinicopathologic presentation of COVID-19 thus parallels that of other thrombotic diseases, such as atypical hemolytic uremic syndrome (aHUS), that are caused by dysregulation of the complement system. This raises the specter that many of the thrombotic complications arising from SARS-CoV-2 infections may be triggered and/or exacerbated by excess complement activation. This is of major potential clinical relevance, as currently available anti-complement therapies that are highly effective in protecting against thrombosis in aHUS, could be efficacious in COVID-19. In this review, we provide mounting evidence for complement participating in the pathophysiology underlying the thrombotic diathesis associated with pathogenic coronaviruses, including SARS-CoV-2. Based on current knowledge of complement, coagulation and the virus, we suggest lines of study to identify novel therapeutic targets and the rationale for clinical trials with currently available anti-complement agents for COVID-19.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Conway EM, Pryzdial ELG. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost. 2020. PMID: 32762081. doi:10.1111/jth.15050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。